March 25th 2016
During the past several years, a wealth of positive clinical trials coupled with an evolution in understanding of neuroendocrine tumors has altered the treatment landscape.
March 15th 2016
The antibodyâ€“drug conjugate sacituzumab govitecan (IMMU-132) received a breakthrough therapy designation based on phase II trial data showing a response rate of 31% in heavily pretreated patients with metastatic TNBC. However, treatment advances are lagging behind those seen in other breast cancer phenotypes.
January 13th 2016
Questions remain in terms of how to optimally sequence and/or combine both targeted agents and immunotherapies in melanoma.
November 17th 2015
With scores of subtypes and a paucity of molecular markers, soft tissue sarcoma remains a complex and challenging tumor type to treat yet significant strides being made in the field are likely to alter the therapeutic paradigm.
September 17th 2015
As new targeted and immunologic agents are introduced for patients with lung cancer, clinicians have more factors to consider than ever before when developing treatment plans for their patients.
August 16th 2015
Recent evidence has shed some light on the prognostic value of microsatellite instability and the potential benefit of checkpoint inhibition in colorectal cancer.